{"log_id": 6790152919037739704, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.010592, "average": 0.926931, "min": 0.692399}, "location": {"width": 304, "top": 160, "height": 37, "left": 274}, "words": "(气道)作用,而非全身性作用"}, {"probability": {"variance": 0.002804, "average": 0.972594, "min": 0.788157}, "location": {"width": 759, "top": 190, "height": 50, "left": 266}, "words": "噻托澳铵与M2受体的解离比与M3受体快,在体外研究中,其对M的受体肥"}, {"probability": {"variance": 0.016626, "average": 0.93966, "min": 0.468177}, "location": {"width": 757, "top": 220, "height": 50, "left": 264}, "words": "型选择性高于M2。高效而与受体解离缓慢使得哪托澳在临床上球为慢性阻"}, {"probability": {"variance": 0.024036, "average": 0.905179, "min": 0.440804}, "location": {"width": 491, "top": 252, "height": 40, "left": 263}, "words": "寒性疾病(COPD)患者显著而长效的支气管扩张药"}, {"probability": {"variance": 0.01281, "average": 0.956143, "min": 0.565434}, "location": {"width": 759, "top": 310, "height": 49, "left": 261}, "words": "临床研究包括:对总数为2663例患者进行的4个为期一年、和2个为期6个月"}, {"probability": {"variance": 0.048238, "average": 0.865443, "min": 0.374125}, "location": {"width": 760, "top": 341, "height": 47, "left": 261}, "words": "的机、双研(英1308接受托澳铵治疗)。为期一年的研究幽两个安"}, {"probability": {"variance": 0.001133, "average": 0.985889, "min": 0.857347}, "location": {"width": 760, "top": 369, "height": 50, "left": 260}, "words": "慰剂对照试验和两个异丙托溴铵对照试验组成;两个为期6个月的试验均用沙美"}, {"probability": {"variance": 0.013237, "average": 0.964075, "min": 0.382475}, "location": {"width": 741, "top": 400, "height": 48, "left": 258}, "words": "特罗( salmeterol)和安慰剂作对照这些研究包括对肺功能以及对呼吸困难"}, {"probability": {"variance": 0.009277, "average": 0.969783, "min": 0.577123}, "location": {"width": 399, "top": 429, "height": 38, "left": 255}, "words": "病情加重和与健康相关的生活质量的测定"}, {"probability": {"variance": 0.016988, "average": 0.945383, "min": 0.395175}, "location": {"width": 757, "top": 487, "height": 49, "left": 259}, "words": "上述研究中,噻托溴铵每一次给药,糕次给药后30分钟内使肺功能(1秒钟"}, {"probability": {"variance": 0.010737, "average": 0.938066, "min": 0.493761}, "location": {"width": 746, "top": 517, "height": 48, "left": 255}, "words": "用力呼气容积(FEV)和用力肺活量(FVC))得到著改善,并持续24小时"}, {"probability": {"variance": 0.004963, "average": 0.97751, "min": 0.632068}, "location": {"width": 761, "top": 545, "height": 51, "left": 254}, "words": "用药第三天时,支气管扩张效应基本达到稳态,药效学稳态在一周内达到。根据"}, {"probability": {"variance": 0.01795, "average": 0.927381, "min": 0.483797}, "location": {"width": 760, "top": 575, "height": 49, "left": 253}, "words": "患者每测定的结果,表明噻振溴铵( SPIRIVA)著改善早、晚的PEFR(峰"}, {"probability": {"variance": 0.029573, "average": 0.905835, "min": 0.351486}, "location": {"width": 763, "top": 604, "height": 50, "left": 251}, "words": "值呼气流遽)。托澳铵在一年的绘药期内一保持其支气扩张作用,而耐受"}, {"probability": {"variance": 0.000105, "average": 0.993149, "min": 0.97541}, "location": {"width": 89, "top": 636, "height": 27, "left": 251}, "words": "现象发生"}, {"probability": {"variance": 0.011338, "average": 0.946933, "min": 0.461031}, "location": {"width": 746, "top": 690, "height": 51, "left": 248}, "words": "对96例慢性阻囊性肺疾病COPD)憋者进行的随机、安慰剂对照临床研究证明"}, {"probability": {"variance": 0.015316, "average": 0.950067, "min": 0.475979}, "location": {"width": 760, "top": 721, "height": 49, "left": 249}, "words": "与安慰剂比,治疗组在给药的24小时间隔期间文气管保持扩张,无论噻托澳"}, {"probability": {"variance": 0.002785, "average": 0.976987, "min": 0.796843}, "location": {"width": 311, "top": 751, "height": 33, "left": 246}, "words": "铵的给药时间是在早上还是晚上"}, {"probability": {"variance": 0.018151, "average": 0.935692, "min": 0.470843}, "location": {"width": 508, "top": 808, "height": 42, "left": 244}, "words": "长期临床试验(为期6个月年)证明了下列结果"}, {"probability": {"variance": 0.015141, "average": 0.930163, "min": 0.531163}, "location": {"width": 761, "top": 866, "height": 51, "left": 241}, "words": "噻托溴铵显著改善呼吸困难(用哈拉转换呼吸困难指数评价),这种改善在整个"}, {"probability": {"variance": 0.005627, "average": 0.937345, "min": 0.791282}, "location": {"width": 177, "top": 899, "height": 27, "left": 241}, "words": "淮疗期间一直持"}, {"probability": {"variance": 0.00088, "average": 0.985346, "min": 0.891452}, "location": {"width": 282, "top": 984, "height": 36, "left": 239}, "words": "临床前安全性资料(毒理学)"}, {"probability": {"variance": 0.000588, "average": 0.991333, "min": 0.897116}, "location": {"width": 763, "top": 1040, "height": 52, "left": 236}, "words": "常规的安全药理学(一般药理学)试验、长期毒性试验和生性试验等研究所"}, {"probability": {"variance": 0.012199, "average": 0.954063, "min": 0.451689}, "location": {"width": 750, "top": 1070, "height": 51, "left": 235}, "words": "观察到的结果均可由噻托溴铵的抗胆碱能特性来解释,特别物摄食量下降"}, {"probability": {"variance": 0.024867, "average": 0.917412, "min": 0.507992}, "location": {"width": 763, "top": 1100, "height": 51, "left": 232}, "words": "体重增加受抑制、干和鼻干、液和液分泌减少、瞳孔放大和心率增加等反"}, {"probability": {"variance": 0.024115, "average": 0.935924, "min": 0.444242}, "location": {"width": 764, "top": 1131, "height": 51, "left": 233}, "words": "应。长期毒性试验观察到其它有关作用为:大鼠和小鼠的轻瘦璃道刺激反应表"}, {"probability": {"variance": 0.006655, "average": 0.972254, "min": 0.550476}, "location": {"width": 750, "top": 1159, "height": 50, "left": 230}, "words": "现为鼻炎和鼻腔及鼻咽部的上皮改变,大鼠前列腺炎伴蛋白沉积和结石"}, {"probability": {"variance": 0.01454, "average": 0.954554, "min": 0.483797}, "location": {"width": 768, "top": 1212, "height": 62, "left": 226}, "words": "只有在产生母体毒性的剂量水平,才能观察到娠、人的发育、分娩"}, {"probability": {"variance": 0.001938, "average": 0.959593, "min": 0.883342}, "location": {"width": 246, "top": 1247, "height": 35, "left": 227}, "words": "或围产期发育的有害作用"}, {"probability": {"variance": 0.030866, "average": 0.886926, "min": 0.481699}, "location": {"width": 815, "top": 1302, "height": 69, "left": 223}, "words": "噻托溴铵对大鼠和家免均无致畸作用。对呼吸道利激佛用尿道(前列腺炎药费"}, {"probability": {"variance": 0.020583, "average": 0.942714, "min": 0.450413}, "location": {"width": 824, "top": 1332, "height": 56, "left": 224}, "words": "的作用和生殖毒性只在局部或全身给药剂量超过淀剂量的5倍以上才观察到"}, {"probability": {"variance": 0.003399, "average": 0.979415, "min": 0.741199}, "location": {"width": 442, "top": 1366, "height": 40, "left": 222}, "words": "基因性和致癌性研究未观察到对人类的危害"}], "language": 3}